BioWorld

Dec. 8, 2004

View Archived Issues

Micromet, Serono Enter Cancer Drug Deal Worth Up To $148M

In a deal just shy of $150 million, Micromet AG partnered with Serono SA its Phase II monoclonal antibody, MT201, designed to treat prostate and metastatic breast cancer. (BioWorld Today) Read More

Endocyte Brings In $22.6M To Advance 'Smart Drugs'

Read More

Ciphergen Rises On Results For Early Cancer Detection

Read More

SemBioSys Genetics Prices IPO: $14.5M For Drug Pair

Read More

Other News To Note

Read More